parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in cone photoreceptor cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	136 Parkinson's papers of 4,693	0.35
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5760

receipt 5768: MAP2 in dopamine neurons, braak

power: full sample +0.47 (p 0.049, n 18), 95% CI +0.01 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: +0.48 (p 0.046, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.46 (p 0.052, n 18). could be the mix.
skeptic: leave-one-out range +0.39 to +0.58, sign flips 0; without severely affected donors +0.47 (p 0.049, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAP2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5767: MAP2 in oligodendrocytes, braak

power: full sample +0.08 (p 0.761, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.761, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.05 (p 0.834, n 18). could be the mix.
skeptic: leave-one-out range -0.04 to +0.21, sign flips 2; without severely affected donors +0.08 (p 0.761, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAP2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts